Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASH Data Give Millennium’s Velcade A Boost, Raise Bar For Competitors

Executive Summary

Myeloma trial data released at the American Society of Hematology meeting promises to further lift utilization for Takeda/Millennium's proteasome inhibitor Velcade, which just passed $1 billion in sales
Advertisement

Related Content

Onyx Sees Blockbuster In Oncology Drug Carflizomib, Buys Proteolix To Get It
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Takeda's Alogliptin Suffers Major Setback, Delaying Drug Launch Until 2012 Or Later
Revlimid gets NICE nod
Revlimid gets NICE nod
2008 Deals Of The Year
2008 Deals Of The Year
ASH Preview: Researchers Chase Winning Combination In Frontline Myeloma
Velcade Wins FDA Clearance In First-Line MM
Velcade As Front-Line Multiple Myeloma Treatment Solidified By Phase III Data
Advertisement
UsernamePublicRestriction

Register

PS050432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel